Tacrolimus Treatment for Refractory Autoimmune Cytopenia

Autoimmune Hemolytic Anemia Clinical Trial

Official title:

Tacrolimus Treatment for Refractory Autoimmune Cytopenia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03918265
• Other study ID #: tacrolimus-2
• Status: Recruiting
• Phase: Phase 4
• Start date: May 4, 2019
• Est. completion date: November 10, 2021

Study information

• Verified date: June 2019
• Source: Peking Union Medical College Hospital
• Contact: Ruoxi Zhang, M.D.
• Phone: +86 18510064839
• Email: rx_zh15[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Autoimmune cytopenia, including autoimmune hemolytic anemia (AIHA), pure red cell aplasia (PRCA), Evans syndrome (ES), usually has good responses to steroids therapies as first line, but there is a considerable percentage of patients who relapse, become refractory or dependent on steroids to maintain an acceptable level of hemoglobin or platelets. The effects of the second line therapy are also not satisfactory and sometimes not available. The investigators aim to explore the efficacy and side-effect of tacrolimus for refractory autoimmune cytopenia.

Description:

Tacrolimus binds FKBP12 with high affinity after entry into cytoplasm, suppresses calcineurin activity and prevents nuclear translocation of transcription factors such as NF-AT that are involved in IL-2 gene transcription. As a result, T-cell activation is inhibited with a subsequent reduction in the production of cytokines that include IL-2, TNF-α, IL-3, IL-4, IFN-γ, IL-6 and IL-10; B-cell activation, class-switching and immunoglobulin production are also attenuated. Reports on the use of tarcrolimus in the treatment of autoimmune cytopenia are anecdotal and describe therapy with a variety of drug dosages.

The purpose of this study is to evaluate the effect of tacrolimus on patients with refractory autoimmune cytopenia, the side-effects will be documented and plasma concentration of tacrolimus will be monitor.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: November 10, 2021
• Est. primary completion date: August 10, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Refractory autoimmune cytopenia, including autoimmune hemolytic anemia, pure red cell aplasia, Evans syndrome.

• 18-80 years old.

• No response or intolerant to first and second line therapies.

• ECOG Performance Status of 0-2

• Written informed consent.

Exclusion Criteria:

• Other diseases which might cause hematological abnormalities.

• Response and well tolerate to first or second line therapy.

• Patients who are under 18-year-old or over 80-year-old.

• Pregnant or lactating.

• Patients unwilling to or unable to comply with the protocol.

Related Conditions & MeSH terms

• Anemia, Hemolytic
• Anemia, Hemolytic, Autoimmune
• Autoimmune Hemolytic Anemia
• Evans Syndrome
• Pure Red Cell Aplasia
• Red-Cell Aplasia, Pure

Intervention

Drug:
• Tacrolimus
On refractory autoimmune cytopenia patients, tacrolimus was tried. Dosage: 1mg bid and tacrolimus trough targets were 5-10 ng/ml throughout the study

Locations

Country	Name	City	State
China	Peking Union Medical College Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Peking Union Medical College Hospital

Country where clinical trial is conducted

China, 

References & Publications (2)

Li Y, Feng X. Efficacy and safety of tacrolimus in systemic lupus erythematosus patients with refractory thrombocytopenia: a retrospective study. Lupus. 2018 Jan;27(1):60-65. doi: 10.1177/0961203317711011. Epub 2017 May 31. — View Citation

Tabchi S, Hanna C, Kourie HR, Aftimos P, El Osta L, Ghosn M. Successful treatment of Evans syndrome with Tacrolimus. Invest New Drugs. 2015 Feb;33(1):254-6. doi: 10.1007/s10637-014-0155-9. Epub 2014 Sep 12. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Hemoglobin level	Hemoglobin level in g/L	6 months
Primary	Platelet count	Platelet count in /L	6 months
Secondary	Hemoglobin level	Hemoglobin level in g/L	2 years
Secondary	Platelet count	Platelet count in /L	2 years